MLL represented AstraZeneca in patent infringement proceedings against Sandoz before the Swiss Federal Patent Court

MLL represented the patent proprietor AstraZeneca in patent infringement proceedings against Sandoz, concerning AstraZeneca’s fulvestrant formulation patent. The Federal Patent Court decided that AstraZeneca’s patent was valid and infringed by Sandoz’s generic product. The fulvestrant formulation, marketed by AstraZeneca under the name Faslodex®, is used to treat breast cancer by intramuscular injection.

The litigation team was composed of MLL’s attorneys-at-law Michael Ritscher (Head of IP – pictured) and Kilian Schärli (partner) as well as European Patent Attorney Thorsten Bausch (partner at Hoffmann Eitle) and MLL’s European Patent Attorney Ulrike Ciesla (partner).

MLL represented AstraZeneca in patent infringement proceedings against Sandoz before the Swiss Federal Patent Court

FabioAdmin

Legalcommunity.ch

Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2022 © All rights Reserved. Design by Origami Creative Studio

SHARE

Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram